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Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. We previously showed
that the inhibition of placental growth factor (PlGF) exerts antitumour effects and induces vessel normalisation,
possibly reducing hypoxia. However, the exact mechanism underlying these effects remains unclear. Because
hypoxia and endoplasmic reticulum stress, which activates the unfolded protein response (UPR), have been
implicated in HCC progression, we assessed the interactions between PlGF and these microenvironmental stresses.
Methods: PlGF knockout mice and validated monoclonal anti-PlGF antibodies were used in a diethylnitrosamine-
induced mouse model for HCC. We examined the interactions among hypoxia, UPR activation and PlGF induction
in HCC cells.
Results: Both the genetic and pharmacological inhibitions of PlGF reduced the chaperone levels and the activation
of the PKR-like endoplasmic reticulum kinase (PERK) pathway of the UPR in diethylnitrosamine-induced HCC.
Furthermore, we identified that tumour hypoxia was attenuated, as shown by reduced pimonidazole binding.
Interestingly, hypoxic exposure markedly activated the PERK pathway in HCC cells in vitro, suggesting that PlGF
inhibition may diminish PERK activation by improving oxygen delivery. We also found that PlGF expression is
upregulated by different chemical UPR inducers via activation of the inositol-requiring enzyme 1 pathway in HCC
cells.
Conclusions: PlGF inhibition attenuates PERK activation, likely by tempering hypoxia in HCC via vessel
normalisation. The UPR, in turn, is able to regulate PlGF expression, suggesting the existence of a feedback
mechanism for hypoxia-mediated UPR that promotes the expression of the angiogenic factor PlGF. These findings
have important implications for our understanding of the effect of therapies normalising tumour vasculature.
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Background
Hepatocellular carcinoma (HCC) ranks as the second
leading cause of cancer-related mortality worldwide [1].
Conventional chemotherapy is ineffective, and targeted
therapy for advanced HCC with sorafenib, which targets
Raf and platelet-derived and vascular endothelial growth
factor (VEGF) receptor tyrosine kinase signalling, shows
only a limited survival benefit [2].
The VEGF signalling pathways play central roles in
angiogenesis [3]. VEGF-A binds to two tyrosine kinase re-
ceptors, VEGFR-1 and VEGFR-2. Most of the biological
effects of VEGF-A are mediated by VEGFR-2 [3]. The pla-
cental growth factor (PlGF, four isoforms: PlGF-1-4) binds
to VEGFR-1 and induces responses in endothelial, malig-
nant, and immune cells [4]. VEGFR-1 has weak tyrosine
kinase activity but a substantially higher binding affinity
for VEGF-A than VEGFR-2. Although VEGFR-1 may act
as a trap for VEGF-A, it also transmits signals in response
to PlGF via its tyrosine kinase domains [4, 5]. A role for
VEGFR-1 during tumour angiogenesis has been suggested
[5, 6]. VEGFR-1 expression in HCC tissues is higher than
that in peritumoural tissues and correlates with worse sur-
vival after resection [7, 8].
Importantly, genetic or pharmacological inhibition of
PlGF reduces tumour growth and induces vessel normal-
isation in different preclinical models, including the
diethylnitrosamine-induced HCC model [5, 9, 10]. Al-
though anti-PlGF antibodies are controversial [11], evi-
dence for the dose and specificity of the anti-PlGF-2
antibody clone 5D11D4 was previously provided [5].
Furthermore, disease stabilization for 12 months has
been observed with anti-human PlGF monoclonal anti-
body TB403 in 2 out of 23 patients with advanced solid
tumours refractory to standard therapy, confirming the
need for a better understanding of the effect of PlGF in-
hibition on tumour biology [12].
The endoplasmic reticulum (ER) consists of a mem-
branous network in which proteins are synthesised,
post-translationally modified and folded. Therefore, the
lumen houses chaperones, including protein disulfide
isomerase A4 (PDIA4), calnexin (CANX), glucose-
regulated protein-78 (GRP78) and −94 (GRP94) [12–
14]. Several perturbations in the protein folding, such
as hypoxia, glucose deprivation and oxidative stress,
lead to the accumulation of unfolded proteins in the
ER, a phenomenon called ER stress. ER stress triggers
the unfolded protein response (UPR), which leads to an
adaptive transcriptional response involved in protein
quality control, redox homeostasis and angiogenesis.
Paradoxically, the UPR also coordinates pro-apoptotic
responses to ER stress [13, 14]. Interestingly, ER stress
is present in human and experimental HCC, and
modulating the UPR could hold important therapeutic
potential [15, 16].
Three major ER stress sensors have been identified, as
follows: PKR-like ER kinase (PERK), inositol-requiring
enzyme 1 (IRE1) and activating transcription factor 6
(ATF6) [13]. The effect of ATF6 on cell fate is primarily
cytoprotective, whereas the effect of IRE1 and PERK is
presumed to be both pro-adaptive and pro-apoptotic
[13, 14, 17]. However, inhibition of the PERK pathway
induces antitumour effects in experimental HCC [14].
Following the release of GRP78, PERK phosphorylates
the eukaryotic initiation factor 2α (eIF2α), leading to the
attenuation of global translation. However, the transla-
tion of certain transcripts, such as activating transcrip-
tion factor 4 (ATF4), is favoured. ATF4 induces genes
involved in protein quality control, amino acid bio-
synthesis and the induction of apoptosis via C/EBP
homologous protein (CHOP) [13]. IRE1 activation re-
sults in X-box-binding protein 1 (XBP1) mRNA spli-
cing to generate a more active spliced XBP1 (XBP1s),
which induces the genes involved in protein folding,
such as endoplasmic reticulum DnaJ homolog 4 (ERDJ4)
and CANX [18]. ATF6 is mobilised to the Golgi, where it
is cleaved, releasing a transcriptionally active fragment,
which in turn induces the expression of homocysteine-
responsive ER-resident ubiquitin-like domain member 1
(HERPUD1), unspliced XBP1 (XBP1u) and chaperones in-
cluding PDIA4 [12, 17].
In this study, we investigated whether vessel normalisa-
tion induced by PlGF blockade modulates the activation
of the UPR or oxygen levels in experimental HCC and
whether PlGF expression is regulated by ER stress. Col-
lectively, we revealed that PlGF inhibition reduced hyp-
oxia and the activation of the PERK pathway of the UPR
in the tumour nodules of the carcinogen-induced mouse
model. Furthermore, PlGF expression was upregulated by
divergent ER stress stimuli in vitro. These results provide
important insight into the reciprocal interactions between
PlGF and the tumour microenvironment.
Methods
Animals
Wild type 129S2/SvPasCrl mice were purchased from
Charles River (Belgium), and PlGF−/− knockout (PlGFKO)
129S2/SvPasCrl mice were obtained from the laboratory
of Angiogenesis & Neurovascular link (Leuven, Belgium).
Both were maintained as previously described [5]. All
mice were genotyped by PCR before the start of the
experiments. PlGF-deficient mice are born at normal
Mendelian ratios and do not show any obvious vascular
anomalities [19]. Five-week-old males received weekly in-
traperitoneal saline or diethylnitrosamine (DEN) (35 mg/
kg, in saline) injections [20]. A murine anti-PlGF mono-
clonal antibody (validated clone 5D11D4 [5]; referred to
as aPlGF) was obtained from Thrombogenics (Leuven,
Belgium). Wild type mice that received DEN for 25 weeks
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were subsequently treated for 5 weeks with aPlGF
(intraperitoneally, 25 mg/kg; 2x/week) or IgG (same regi-
men, n = 10 in each group). Wild type mice that received
saline for 25 weeks were subsequently treated for 5 weeks
with aPlGF (same regimen) or IgG (same regimen, n = 10
in each group). Pimonidazole HCl (Hypoxyprobe-1 Inc.,
Burlington, MA, USA) was intraperitoneally administered
to 4 random mice per group in a single dose of 60 mg/kg
one hour before sacrifice. Male PlGFKO mice and their
wild type littermates received DEN for 30 weeks (n = 12 in
each group). After 30 weeks, blood was collected from the
retro-orbital sinus under isoflurane anaesthesia. After
macroscopic evaluation and the quantification of the
number of hepatic tumours with a minimum diameter of
2 mm, the livers were fixed in 4 % phosphate-buffered for-
maldehyde (Klinipath) and embedded in paraffin or snap
frozen in liquid nitrogen. Tumour nodules were isolated
by microdissection (Carl Zeiss, Bernreid, Germany) for ex-
pression analysis. Haematoxylin/eosin and reticulin stain-
ing were performed to assess the tumour burden, and the
results were assessed by 2 independent observers. All pro-
tocols were approved by the Ethical Committee of experi-
mental animals at the Faculty of Health Sciences, Ghent
University, Belgium (ECD 11/52).
Cell culture
HepG2 (HB-8065; ATCC, Virginia, USA), Hep3B (HB-
8064; ATCC) and Huh7 (kindly provided by Dr. Olivier
Govaere (University of Leuven, Belgium)) cells were cul-
tured in DMEM supplemented with 10 % foetal bovine
serum (Life Technologies, Ghent, Belgium). None of the
three cell lines used require ethical approval. Cells were
incubated for 24 h or 48 h with a PERK inhibitor
(0.3 μM; GSK2656157, NoVi Biotechnology, Shandong,
China), an IRE1 inhibitor (8 μM; 4μ8C, Calbiochem,
Massachusetts, USA), tauroursodeoxycholic acid
(TUDCA, 1 mM), tunicamycin (1 μM), thapsigargin
(150 nM) or quercetin (100–300 μM) and compared to
equal volumes of solvent. All reagents were obtained
from Sigma (Diegem, Belgium) unless stated otherwise.
Hypoxic atmosphere (1 % oxygen) was established in a
hypoxic chamber (AnaeroGen; Oxoid, Basingstoke,
UK). Experiments were carried out in quadruplicate
and independently repeated three times.
Detailed information regarding total RNA extraction,
quantitative real-time PCR, Western blotting, and im-
munohistochemistry is provided in the Additional file 1.
Statistics
Statistical analyses were performed using SPSS 21 (SPSS,
Chicago, USA). Values are presented as the means ± SD
or fold change relative to the mean expression in con-
trols. Kolmogorov-Smirnov test was used to test for nor-
mality. Normally distributed data were subjected to the
unpaired Student’s t-tests. Multiple groups were com-
pared by one-way analysis of variance (ANOVA) with
Bonferroni correction. Non-normally distributed data
were tested using the Mann–Whitney U-test. Two-tailed
probabilities were calculated; a p-value less than 0.05
was considered statistically significant.
Results
PlGF inhibition induces antitumour effects and vessel
normalisation in experimental HCC
First, we validated the previously reported antitumour
effects and vessel normalisation induced by PlGF block-
age [5, 9]. When wild type mice with established HCC
were treated with aPlGF (n = 10) or IgG (n = 10) from
25 weeks onward for 5 weeks, 20 % of mice receiving
control IgG died, whereas only 10 % died in the aPlGF
group. Additionally, aPlGF-treated mice developed fewer
nodules per liver (all sizes: 17.6 ± 4.9 after IgG versus
12.7 ± 3.2 after aPlGF; p < 0.05). After 30 weeks of DEN
administration to wild type (n = 12) or PlGFKO (n = 12)
mice, 25 % of wild type mice compared to 16 % of
PlGFKO mice succumbed, and fewer tumour nodules
per liver were observed in PlGFKO mice (22.4 ± 4.8 in
wild type versus 15.8 ± 6.2 in PlGFKO; p < 0.05). Further-
more, several capillaries in control HCC nodules had an
abnormal shape and size (Additional file 2: Figure S1A).
In PlGF-blocked tumours, fewer capillaries, as shown by
endoglin staining, were tortuous (aPlGF: p < 0.05 and
PlGFKO: p < 0.01; Additional file 2: Figure S1B). These
results confirm that PlGF blockage induces antitumour
effects and partially normalises the abnormal tumour
vessel structure.
PlGF inhibition reduced chaperone expression and
activation of the Perk pathway in experimental HCC
We among others previously described the UPR pattern
in DEN-induced HCC [15]. Here, we evaluated the effect
of PlGF inhibition on this pattern in isolated tumours.
The administration of aPlGF downregulated the mRNA
expression of the ER stress-induced chaperones Grp78
and Grp94 in the tumours, compared to the IgG group
(p < 0.05; Fig. 1a). Additionally, the PlGFKO mice that
received DEN for 30 weeks showed reduced levels of
Grp78 (p < 0.05) and Grp94 (p < 0.05) in the tumours
compared to their wild type littermates. Western blot-
ting demonstrated reduced protein expression of Grp78
in the tumours of the aPlGF-treated and PlGFKO mice
compared to those of the IgG-treated and wild type con-
trol group, respectively (Fig. 1b).
The Ire1-mediated splicing of Xbp1 was unaltered by
PlGF inhibition (Fig. 1c). Accordingly, the targets of
Xbp1s, Canx and Erdj4, showed a similar expression
level compared to the corresponding controls.
Vandewynckel et al. BMC Cancer  (2016) 16:9 Page 3 of 10
Western blot analysis (Fig. 1b and Additional file 3:
Figure S2) and immunostaining (Fig. 1e) showed that
the Perk-mediated phosphorylation of eIf2α was reduced
in the HCC tissues of aPlGF-treated and PlGFKO mice
compared to IgG-treated and wild type controls resp..
Atf4 mRNA (aPlGF: p < 0.05 and PlGFKO: p < 0.01;
Fig. 1d) and protein (Fig. 1b) expression in the nodules
were decreased by PlGF inhibition. Further, Chop mRNA
(p < 0.05; Fig. 1d) and protein (Fig. 1b) levels were de-
creased. Next, we assessed the expression of Growth ar-
rest and DNA damage-inducible protein (Gadd34), which
initiates eIf2α dephosphorylation leading to a negative
Fig. 1 PlGF inhibition tempers the activation of the UPR in an orthotopic mouse model of HCC. a Quantitative real-time PCR analysis of the ER
chaperones Grp78, Grp94 and Pdia4 and Herpud1 in aPlGF-treated and PlGFKO mice. Relative fold changes were calculated using the ΔΔCT
method. b Immunoblotting for UPR-mediated proteins. c Quantitative real-time PCR analysis of ER chaperones of Ire1-mediated splicing of
Xbp1 and Ire1 targets Canx and Erdj4, d Perk-related genes Atf4, Chop and Gadd34. *p < 0.05, **p < 0.01, ***p < 0.001. IgG = 25w DEN + 5w IgG,
aPlGF = 25w DEN + 5w aPlGF, WT = 30w DEN in wild type (WT) mice, PlGFKO = 30w DEN in PlGF−/− knockout mice. e Immunostaining for
phospho-eIf2α in mouse livers following the indicated treatment. Scale bars: 100 μm
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feedback loop of the Perk pathway [13]. Gadd34 levels
were unaltered (Fig. 1b and d), indicating that PlGF inhib-
ition did not enhance this negative feedback loop. Also,
the mRNA and protein levels of the UPR sensor Perk itself
were unaltered, excluding a direct effect of PlGF on Perk
expression (Additional file 4: Figure S3A-B). Overall, these
data indicate that PlGF inhibition indirectly diminished
Perk signalling in HCC.
To examine the Atf6 pathway, Pdia4 and Herpud1
mRNA expression was monitored (Fig. 1a). Only Pdia4
mRNA was downregulated in the tumours of PlGFKO
mice compared to their wild type littermates (p < 0.05).
Importantly, wild type mice that received saline for
25 weeks and were subsequently treated with aPlGF for
5 weeks demonstrated no significant differences in the
hepatic mRNA expression of the selected UPR targets
compared to those receiving control IgG treatment (data
not shown). Thus, these results demonstrate that PlGF
inhibition reduces the intratumour expression of chaper-
ones, such as Grp78, Grp94 and Pdia4, as well as the ac-
tivation of the Perk pathway.
PlGF inhibition reduces intratumour hypoxia
We previously showed that PlGF inhibition induces ves-
sel normalisation (Additional file 2: Figure S1; [5, 21]).
To investigate whether these vascular changes were
functionally relevant or, in other words, whether PlGF
inhibition effectively increased the oxygen levels in the
hepatic tumours of the used mouse model, we applied
pimonidazole, a molecule that binds only hypoxic areas
in vivo and can be detected after sacrifice by im-
munohistochemistry (Fig. 2a). Indeed, administration of
aPlGF significantly reduced tumoural pimonidazole
binding (p < 0.05; Fig. 2a-b). To improve the quantifica-
tion method of the binding of pimonidazole, Western
blotting for detection of pimonidazole adducts in iso-
lated DEN-induced tumours was performed (Fig. 2c).
Densitometry analysis confirmed that the liver tumours
were characterized by increased pimonidazole binding
and that administration of aPlGF reduced pimonidazole
binding in the tumours (p < 0.05; Fig. 2c-d). Finally,
aPlGF downregulated the expression of hypoxia-
inducible genes Glut1 (p < 0.05) and Pfk (p = 0.07) in the
DEN-induced HCC nodules (Fig. 2e). Thus, aPlGF ef-
fectively tempered the induction of tumour hypoxia.
Hypoxia activates the PERK pathway
Because PlGF inhibition reduced tumour hypoxia and
PERK activation in vivo, we questioned whether hypoxia
mediates PERK activation in HCC cells. Therefore, we
examined the effect of hypoxia (<1 % O2 or 7.6 mmHg
[22]) for 24 h or 48 h on the expression of PERK targets
in HepG2, Huh7 and Hep3B cells (Fig. 3a-b). Hypoxic
exposure upregulated the mRNA expression of GRP78
(p < 0.001), ATF4 (p < 0.05), CHOP (p < 0.001) and
GADD34 (p < 0.001). Furthermore, hypoxic exposure also
increased the phosphorylation of eIF2α (24 h: p < 0.05 and
48 h: p < 0.01; Fig. 3b-c) and protein expression of ATF4
and CHOP (Fig. 3b). Accordingly, hypoxic exposure sig-
nificantly upregulated CHOP and GADD34 mRNA in
Huh7 and Hep3B cells (Fig. 3d-e). These data indicate that
hypoxic exposure causes potent activation of the PERK
pathway in HCC cells.
Activation of the IRE1 pathway promotes PlGF expression
Because the UPR is activated in HCC and PlGF inhib-
ition is able to reduce activation of at least the Perk
branch of the UPR, we next analysed the effect of ER
stress on PlGF expression in vitro. Therefore, we used
two different ER stress inducers: tunicamycin, an in-
hibitor of protein glycosylation, and thapsigargin, an in-
hibitor of sarcoplasmic/endoplasmic reticulum Ca2+
ATPases [13, 23]. Both significantly increased the mRNA
levels of PlGF (Fig. 4a). As shown in Fig. 4b, an increase
in the expression of faster-migrating unglycosylated
PlGF was detected in HepG2 cells treated with tunica-
mycin. The addition of the chemical chaperone TUDCA
to tunicamycin-treated cells attenuated the ER stress-
mediated induction of PlGF mRNA (p < 0.01), whereas
the addition of TUDCA to untreated cells had no effect
on the PlGF mRNA levels (Fig. 4a). Addition of a
small-molecule inhibitor of the IRE1 pathway reduced
the tunicamycin-mediated upregulation of PlGF mRNA
(p < 0.001, Fig. 4a) and protein (Fig. 4b-c) levels. In con-
trast, the addition of a small-molecule inhibitor of the
PERK pathway did not affect PlGF expression. These
data show that the ER stress-mediated upregulation of
PlGF is primary regulated by the IRE1 pathway of the
UPR. Finally, we assessed the effect of UPR activation
on the expression of VEGF mRNA and observed that
also VEGF was significantly upregulated by the ER stress
inducers (p < 0.001, Fig. 4d). However, in contrast to PlGF
mRNA, we observed that VEGF transcription is regulated
by both the IRE1 and PERK pathway (p < 0.05) and is not
attenuated by TUDCA.
Discussion
Growing tumours are often subjected to deficiencies in
vital nutrients and oxygen. These inadequate extracellu-
lar conditions can adversely affect the environment of
the ER and impinge on the maturation of nascent pro-
teins. We recently reported that PlGF inhibition induces
vessel normalisation, potentially supporting the delivery
of nutrients and oxygen to tumour cells [5, 24, 25].
In this study, we found that PlGF inhibition reduced
intratumour hypoxia and ER stress levels (Fig. 5). In fact,
PlGF inhibition attenuates the carcinogen-induced up-
regulation of chaperones, such as Grp78 and Grp94, and
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the activation of the Perk pathway without affecting Ire1
activation. These chaperones and Perk activation are
pro-survival and pro-proliferative modulators in tumour
cells [13–26]. Probably, the aPlGF-mediated reduction of
these UPR factors tempers the aggressive growth of
HCC cells.
Recently, hypoxia-inducible factor-1α (HIF-1α), a key
transcription factor in the cellular response to hypoxia,
was shown to be an important driver of HCC growth
[27]. In this study, we showed that PlGF inhibition re-
duced tumour hypoxia and PERK activation in vivo and
that hypoxia activates the PERK/phospho-IF2α/ATF4
cascade in HCC cells, suggesting that tumour hypoxia
mediates the observed PERK activation in HCC. Pos-
sibly, tumour hypoxia is also involved in the pronounced
activation of PERK in other tumour types, such as
Fig. 2 PlGF inhibition reduces intratumour hypoxia in experimental HCC. a Immunostaining for pimonidazole in mouse livers following the
indicated treatment. Arrows indicate tumours. Scale bars: 100 μm. b Quantification of the immunostaining for pimonidazole. c Lysates of control
liver tissue or isolated DEN-induced tumours were subjected to Western blotting for detection of pimonidazole adducts (Pimo). Blotting of
β-actin is shown as a loading control. d Densitometry analysis of the pimonidazole blot in (c). e Real-time PCR analysis of Glut1 and Pfk mRNA
levels in tumour tissues. IgG = 25w DEN + 5w IgG, aPlGF = 25w DEN + 5w aPlGF. Data are presented as the means ± SD. *p < 0.05
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glioma [28]. Finally, because PERK is, next to hypoxia,
able to stimulate tumour growth [13, 29], the normal-
isation of tumoural oxygen levels by PlGF inhibition is
able to dually target pro-survival signalling via reduced
activation of the HIF-1α and PERK pathway.
Because PlGF inhibition was previously reported to re-
duce experimental liver fibrosis [30], the contribution of
hypoxia and ER stress modulation, which both have
been implicated in fibrogenesis [31, 32], to this outcome
requires further investigation.
Fig. 3 Hypoxia activates the PERK pathway in HCC cells. a HepG2 cells were cultured in normoxia or hypoxia for 24 h or 48 h. The PERK targets,
GRP78, ATF4, CHOP and GADD34 mRNA were detected by Real-time PCR analysis. b Expressions of phospho-eIF2α, eIF2α, ATF4, and CHOP protein
in HepG2 cells were detected using Western blotting. All experiments were repeated three times with similar results. c Densitometry analysis of
the ratio of phosphorylated eIf2α to total eIf2α bands normalised to tubulin and relative to the corresponding control. Quantitative results of the
phosphorylation of eIf2α are presented as the mean ± SD. d Real-time PCR analysis of the PERK targets in Huh7 and e Hep3B cells. *p < 0.05,
**p < 0.01, ***p < 0.001
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Whereas the UPR has previously been shown to up-
regulate several angiogenic factors, including VEGF [33],
this is, to our knowledge, the first report to demonstrate
the induction of PlGF by ER stress in tumour cells. Be-
cause studies on transgenic mice have revealed that
PlGF expression is restricted to pathological conditions
[34], the further investigation of the role of ER stress in
the selectivity of PlGF expression to pathological
conditions, potentially characterised by ER stress, is indi-
cated. Finally, the role of the UPR in vessel abnormalisa-
tion induced by excessive production of angiogenic
factors requires further investigation [34].
Vice versa, the effect of therapies modulating tumour
angiogenesis on the UPR activation pattern, which
affects tumour growth, is currently unknown. To our
knowledge, this is the first study to provide evidence that
vessel normalisation regulates the UPR in cancer cells.
We speculate that anti-VEGF therapies may exert their
therapeutic effect in part by UPR modulation.
The promising preclinical findings of anti-PlGF in
HCC but also in other tumour types such as medullo-
blastoma [35], together with the acceptable safety profile
of anti-PlGF administration in Phase I clinical trials,
have attracted attention to PlGF as a potential target for
therapy. However, improved understanding of the effect
on tumour biology is required. This study indicates that
anti-PlGF modulates the tumour microenvironment and
cell adaptation mechanisms, which have been linked to
tumour behavior [13, 36].
Fig. 5 Schematic model outlining the interactions among PlGF, ER
stress and hypoxia and their effects on HCC growth
Fig. 4 ER stress induces PlGF and VEGF expression in HepG2 cells. a Relative PlGF mRNA levels in HepG2 cells treated for 48 h with the indicated
treatments. TUDCA: tauroursodeoxycholic acid. b Immunoblotting of cell lysates was performed to detect PlGF protein levels. All experiments
were repeated three times with similar results. c Densitometry analysis of the PlGF bands normalized to tubulin and relative to the control.
Quantitative results are presented as the mean ± SD. d Relative VEGF mRNA levels in HepG2 cells treated for 48 h with the indicated treatments.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to the indicated group
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Conclusions
In summary, we have shown that inhibition of PlGF
tempers UPR activation in HCC, most likely by im-
proved oxygen delivery via the induced normalisation of
tumour vessels. Moreover, we revealed that the UPR, in
turn, regulates the expression of PlGF in HCC cells.
Thus, our study sheds light on the reciprocal interac-
tions between PlGF, hypoxia and the UPR and suggests
that the antitumour effects of angiogenesis-modulating
therapy could be mediated by modifying the tumour mi-
croenvironmental stresses in HCC.
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Additional file 1: Supplementary methods. Detailed information
regarding total RNA extraction, quantitative real-time PCR, Western
blotting, and immunohistochemistry. (DOCX 30 kb)
Additional file 2: Figure S1. PlGF blockage induces vessel
normalization. (A) Immunostaining for the endothelial marker endoglin
(CD105). In HCC nodules, the capillary network is chaotically organized
with tortuous vessels (indicated by red arrows) laying at large distances
from each other. However, the capillaries in HCC after aPlGF treatment or
in PlGFKO mice have a more normal appearance with regular pattern,
size, and shape (indicated by green arrows). Black arrows and dashed
lines indicate tumours. (B) Quantification of tortuous vessels per mm2;
n = 5; *p < 0.05, **p < 0.01. (TIFF 16370 kb)
Additional file 3: Figure S2. Densitometry analysis of the phosphorylation
of eIf2α in isolated HCC. (A) Densitometry analysis of the ratio of
phosphorylated eIf2α to total eIf2α bands normalized to tubulin
and relative to the corresponding control. Quantitative results of
phosphorylation of eIf2α are presented as the mean ± SD. *p < 0.05.
(TIFF 4834 kb)
Additional file 4: Figure S3. Effect of PlGF inhibition on the expression
of the UPR sensor Perk. (A) Quantitative real-time PCR analysis of Perk.
Relative fold changes were calculated using the ΔΔCT method. IgG =
25w DEN + 5w IgG, aPlGF = 25w DEN + 5w aPlGF, WT = 30w DEN in
wild type (WT) mice, PlGFKO = 30w DEN in PlGF−/− knockout mice.
(B) Immunoblotting for Perk protein. (TIFF 8720 kb)
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